Vyre Network is growing and with that growth Connector Mario Chelsea joins the team

'Virtual Teams for Dummies' Author Offers Strategies to the New Virtual Workforce

Take The Lead's Co-Founder and President Gloria Feldt Unveils Nine New Leadership Power Tools at Event

A successful Los Angeles film editor discusses her tips on working from home during this worldwide pandemic.

Remote Worker + Virtual Team Support

Niche jewelry company creates unique necklace dedicated to anyone burning the candle from both ends.

Skills-Building Sessions To Offer Attendees Leadership and Career Advancement Tools

Scribendi secures Great Place to Work® certification for 2020.

Cover Girl has launched its newest clothing line in activewear on Amazon exclusively with e-commerce experts Quantum Networks.

Biopharma shares have outperformed the broader market year-to-date, giving rise to apprehension over whether a pullback is in the offing. An analyst at BofA Securities said Friday that now is the time to go from defensive to offensive in the sector, as quarantines are winding down in several parts of the globe.The Biopharma Analyst Analyst Geoff Meacham shortlisted Eli Lilly And Co (NYSE: LLY), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Bristol-Myers Squibb Co (NYSE: BMY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Amgen, Inc. (NASDAQ: AMGN) as biopharma stocks where he would put his money to work.The analyst has the following ratings and price targets for the shares: * Lilly: Buy/$165 * Vertex: Buy/$300 * Bristol-Myers Squibb: Buy/raised the price target from $75 to $80 * BioMarin: Buy/lifted price target from $110 to $120 * Amgen: Buy/price target increased from $265 to $2755 Reasons For BofA's Bullish Disposition BofA is increasingly bullish on the biopharma group due to the following factors, Meacham said: * Expectations for robust revenue growth of 6% in the second half of 2020 compared to the first-half, which is double that of the S&P 500's revenue growth. * Reasonable price-earnings for the stocks in the sector. * Many value-creating events lined up for the second half. * Lower policy risk stemming from goodwill earned from the COVID-19 pipeline. * A consistently positive FDA backdrop.Q1 Earnings Get 'A' Grade All of the big biotechs and major pharma companies reported both revenue and adjusted EPS beats in the first quarter, with Lilly and Vertex even raising some parts of their 2020 guidance, Meacham said.Citing slower new starts and forex headwinds, Bristol-Myers Squibb and BioMarin lowered their 2020 revenue guidance, but maintained their EPS guidance, the analyst said. Meacham expressed surprise at Merck & Co., Inc. (NYSE: MRK) and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) lowering their 2020 revenue and adjusted EPS guidance, given his belief that oncology or orphan diseases wouldn't be as sensitive to COVID-19 disruption.See also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Lilly One of The Higher Quality Stocks In BofA's Coverage Lilly is a source of differentiated growth given its early product cycle and diversified base business, including diabetes, immunology and immunotoxicology and migraine, and an advancing late-stage pipeline of potentially best-in-class or first-in-class therapies, Meacham said.The analyst said he likes Lily's potential for additional earnings growth in 2020-2021 and views Lilly as one of the higher quality stocks in his coverage despite its higher valuation. The prospects for 2021 look attractive, with selpercatinib potentially launching in non-small cell lung cancer and thyroid cancer by year's end, and tirzepatide approval in 2021 representing a "step change" for the diabetes franchise, he said. Consensus For Vertex To Move Higher? Vertex has a richer -- though well-deserved -- valuation, due to its differentiated growth profile, Meacham said.Given that Vertex's commercial execution is largely unaffected by the COVID-19 pandemic, the analyst said investors will begin to look forward to 2021 sooner than for other companies with more commercial risk.BofA expects consensus estimates to continue to move higher, making Vertex's valuation even more attractive.Bristol-Myers Has Highly Differentiated Growth With an estimated 8% revenue growth and 19% EPS growth in 2021 compared to 5-6% and 12%, respectively, for peers, and with six new launches expected this year, 2020 is shaping up to be a very robust period for Bristol-Myers despite the ongoing COVID-19 headwinds, Meacham said. The analyst said the company's growth looks highly differentiated.An increasingly diversified product mix and beatable launch expectations position the company for meaningful upside to consolidated P&L, with improving synergies, he said. BioMarin's 'Game-Changing' Late-Stage Pipeline BioMarin's late-stage pipeline in valrox and vosoritide have improved its growth outlook, Meacham said.The analyst termed the company's late-stage pipeline as "game-changing." The second-half launch of Roctavian is the most important catalyst for the company this year, with the product likely to accelerate the company's already above-average growth profile, he said. "We see BioMarin as one of the higher quality names in our coverage universe given its clean growth story and it remains our SMid cap top pick." Amgen Looks To New Product Growth To Compensate For Legacy Product Erosion The long-term outlook for Amgen's Otezla is improving given the recently announced Phase 3 data for mild-to-moderate psoriasis, Meacham said.The company rapidly refocused its story from legacy product erosion to new product growth with the acquisition of Otezla from the Bristol/Celgene deal, the analyst said. "Since then Amgen's growth profile has only improved, led by an expanded addressable market for Otezla, outperforming Amgen Biosimilars and Evenity franchises, aggressive formulary negotiation for Aimovig, and an exciting pipeline in AMG 510 and tezepelumab looking to contribute as soon as 2021." The Price Action The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) was last seen trading up 1.25% to 128.76, adding to its 5.6% year-to-date gain. Related Link: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace See more from Benzinga * The Daily Biotech Pulse: Ayala IPO, Pluristem Starts Phase 2 Trial Of COVID Treatment, European Nod For Takeda * The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500 * The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The Czech Republic and the United States have signed a joint declaration Wednesday for cooperating on security of 5G technology.

read more

Beautiful work. R u based in Muscat. So am I. Could u pls tell me where u purchase the crochet threads.

I too use coloring pages for my art work from time to time. I can't draw but I'm good at tracing a coloring page onto fabric or paper! HA Works for me! Your workmanship is outstanding!

Beautiful work as always Nima. I love the rich colours you used.

Strategic communications agency Portland has won the PRCA 2020 'Best IPO' campaign award for its support to Baladna's IPO on the Qatar Stock Exchange.

The new framework uses contrastive learning to improve image analysis in unlabeled datasets.

LONDON (Reuters) - More commuters should consider cycling or walking when Britain's coronavirus lockdown is eased to take the pressure off public transport capacity that is likely to drop by 90% under social distancing requirements, Transport Minister Grant Shapps said on Saturday. He urged people to continue to work from home where possible, but said those who did have to commute to work should consider cycling or walking rather than using their cars

The post UK commuters face cycling or walking to work once lockdown is eased appeared first on Firstpost.

Tammy Erickson, McKinsey Award-winning author.

Tammy Erickson, McKinsey Award-winning author.

Marshall Goldsmith, executive coach.

Dick Beatty, professor of human resource management at Rutgers University and coauthor of "The Differentiated Workforce."

David Silverman, author of "Typo: The Last American Typesetter or How I Made and Lost 4 Million Dollars."

Peter Cappelli, Wharton School professor and coauthor of "Managing the Older Worker: How to Prepare for the New Organizational Order."

Stefano Puntoni, professor at the Rotterdam School of Management and author of the HBR article "The Color Pink Is Bad for Fighting Breast Cancer."

Dan McGinn and Scott Berinato, HBR senior editors.

Rob Cross, associate professor at the University of Virginia's McIntire School of Commerce and coauthor of the HBR article "A Smarter Way to Network."

Stephanie Coontz, professor of history at The Evergreen State College and author of "A Strange Stirring."

Kareem Abdul-Jabbar, basketball legend, New York Times best-selling author, and filmmaker.

Paul Polman, CEO of Unilever.

Christine Porath, associate professor at Georgetown University's McDonough School of Business and coauthor of the HBR article "The Price of Incivility."

Julian Birkinshaw and Jordan Cohen, coauthors of the HBR article "Make Time for the Work that Matters."

Joan C. Williams, Distinguished Professor of Law at the University of California and coauthor of the forthcoming book, "What Works for Women at Work."

Jeffrey Joerres, CEO of ManpowerGroup, on finding the talent you need in an unpredictable world.

Stewart D. Friedman, Wharton professor and author of "Baby Bust," presents new research.

Erin Meyer, affiliate professor at INSEAD and author of "The Culture Map," on why memorizing a list of etiquette rules doesn't work.

Dorothy Leonard, author of "Critical Knowledge Transfer" ​and Harvard Business School professor, on retaining organizational expertise.

Erin Reid of Boston University on why men (but not women) feign long working hours.

Phil Libin discusses the impact of technology--from Microsoft Word to wearables--on our collaboration and productivity.

Kimberly Elsbach, author of the HBR article "Collaborating with Creative Peers," on collaborating better with a certain type of colleague.

Gareth Jones, author of "Why Should Anyone Work Here?", explains the things managers know, but struggle to do.

In every issue, we feature a conversation with someone who's been wildly successful outside the traditional business world. This time, it's an astrophysicist.

Emma Seppälä, Stanford researcher and author of "The Happiness Track," explains the proven benefits of a positive outlook; simple ways to increase your sense of well-being; and why it's not about being ecstatic or excited all the time.

Kira Hudson Banks, Ph.D., is an Assistant Professor in the department of psychology at Saint Louis University, and a principal at consulting firm the Mouse and the Elephant. We spoke with her about why managers shouldn't wait for a controversy to start talking about race.

Pay transparency is actually a way better system than pay secrecy. David Burkus, professor at Oral Roberts University and author of "Under New Management," explains why.

Karen Dillon, author of the "HBR Guide to Office Politics", explains how to gracefully decline excessive projects–and thankless tasks.

Iconic relationship expert Dr. Ruth discusses what she's learned over a long career.

Managers play a huge role in their employees' personal lives, which in turn affects productivity, morale, and turnover at work. Professor Scott Behson, author of "The Working Dad's Survival Guide," and professor at Fairleigh Dickinson University, gives practical tips for being a leader who is flexible, fair, and effective.

Anne-Marie Slaughter on (finally) bringing sanity to the work/life struggle.

Moira Weigel explains how the changing nature of work has reshaped the way we meet, date, and fall in love. She's the author of "Labor of Love: The Invention of Dating" and is completing a Ph.D. at Yale University.

Joan C. Williams, distinguished professor and director of the Center for WorkLife Law at UC Hastings, discusses the white working class voters who helped elect Republican Donald Trump as U.S. President, and why Democrat Hillary Clinton did not connect with them.